Quick Answer
SUTRO BIOPHARMA, INC. reported Revenue (ASC 606) of $102.48 million for fiscal year 2025.
SUTRO BIOPHARMA, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $102.48M | +65.2% |
| 2024 | $62.04M | -59.6% |
| 2023 | $153.73M | +126.8% |
| 2022 | $67.77M | +9.5% |
| 2021 | $61.88M | +44.8% |
| 2020 | $42.72M | -0.0% |
| 2019 | $42.74M | +11.2% |
| 2018 | $38.42M | -25.7% |
| 2017 | $51.74M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.69M | +13.8% | -84.8% |
| June 30, 2025 | $63.74M | +148.0% | +266.4% |
| March 31, 2025 | $17.40M | +33.8% | +104.2% |
| September 30, 2024 | $8.52M | -49.7% | -66.9% |
| June 30, 2024 | $25.71M | +146.9% | +97.6% |
| March 31, 2024 | $13.01M | +2.6% | -23.1% |
| September 30, 2023 | $16.92M | -32.7% | +62.5% |
| June 30, 2023 | $10.41M | -62.9% | -17.8% |
- SUTRO BIOPHARMA, INC. showed an increase of +65.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, SUTRO BIOPHARMA, INC.’s revenue (asc 606) has grown by 98.1% (from $51.74 million to $102.48 million).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: